Compare Globus Medical Inc. Class A Common Stock (GMED) vs PulteGroup, Inc. (PHM) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

PulteGroup (PHM) trades at $109.35, down 1.61% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though it beat expectations in Q2 2026. Fundamentally, the company maintains solid profitability with 11.62% net margin and attractive valuation at 11.4 P/E. Analyst consensus remains mixed with 45% buy ratings but a $139.64 price target suggesting 28% upside potential from current levels.

PHM presents a value opportunity with strong cash flow generation and dividend yield, though near-term headwinds from rising interest rates and housing affordability concerns create volatility. The stock's current discount to analyst targets and reasonable valuation metrics support long-term potential, but investors should monitor Q3 2026 earnings on October 22 for confirmation of business resilience.